Eli Lilly Raises Weight-Loss Drug Prices in Canada Amid Trump Influence
In response to pressure from the Trump administration, Eli Lilly & Co. has increased prices for its diabetes and anti-obesity drugs, including Mounjaro, in Canada and the UK. The company is aligning prices in these markets to offset potential lower revenue in the United States, where the administration aims to reduce drug costs. Consequently, the wholesale price of Mounjaro has more than doubled in Canada, with the Kwikpen format now costing up to $773 per dose depending on the dosage, which has raised concerns about accessibility. Although Lilly supports the administration’s goal of maintaining the US as a leader in biopharmaceutical research, the company does not support tariffs, which could raise costs and limit patient access.
John Q. Hosedrinker 
Matt Underwood